1. 2004
2. Published

   Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease

   Hughes, D. & Hughes, D. A., 1 Nov 2004, In: Value in Health. 7, 6, p. 753

   Research output: Contribution to journal › Article › peer-review

3. Published

   From efficacy to effectiveness and cost-effectiveness: modelling possibilities

   Hughes, D. & Hughes, D. A., 1 Nov 2004.

   Research output: Contribution to conference › Paper

4. Published

   HLA-B*5701 and abacavir hypersensitivity - Reply.

   Hughes, D., Hughes, D. A., Park, B. K. & Pirmohamed, M., 1 Nov 2004, In: Pharmacogenetics. 14, 11, p. 784

   Research output: Contribution to journal › Article › peer-review

5. 2005
6. Published

   Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.

   Hughes, D., Hughes, D. A., Bodger, K., Bytzer, P., De Herdt, D. & Dubois, D., 1 Jan 2005, In: Pharmacoeconomics. 23, 10, p. 1031-1041

   Research output: Contribution to journal › Article › peer-review

7. Published

   Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

   Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Jan 2005, 2005 ed. Unknown.

   Research output: Book/Report › Commissioned report

8. Published

   Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Sweden.

   Hughes, D. & Hughes, D. A., 1 Jan 2005, 2005 ed. Unknown.

   Research output: Book/Report › Commissioned report

9. Published

   Welsh Health Economics Network (WHEN): Scoping Report.

   Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Jan 2005, 2005 ed. Unknown.

   Research output: Book/Report › Commissioned report

10. Published

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Feb 2005, In: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, p. 29-38

    Research output: Contribution to journal › Article › peer-review

11. Published

    Empirical analysis of the relationship between dose and duration of drug action

    Hughes, D. & Hughes, D. A., 1 Jun 2005.

    Research output: Contribution to conference › Paper

12. Published

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Jun 2005.

    Research output: Contribution to conference › Paper

13. Published

    Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.

    Hughes, D. & Hughes, D. A., 1 Jul 2005, In: European Journal of Cancer. 41, 11, p. 1655

    Research output: Contribution to journal › Article › peer-review

14. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Jul 2005.

    Research output: Contribution to conference › Paper

15. Published

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Nov 2005, In: QJM - An International Journal of Medicine. 98, 11, p. 829-836

    Research output: Contribution to journal › Article › peer-review

16. Published

    Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

    Hughes, D., Hughes, D. A. & Cowell, W., 1 Nov 2005.

    Research output: Contribution to conference › Paper

17. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Nov 2005.

    Research output: Contribution to conference › Paper

18. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Nov 2005.

    Research output: Contribution to conference › Paper

19. Published

    Trends and influences on use of antidiabetic drugs in England, 1992-2003.

    Walley, T., Hughes, D. & Kendall, H., 1 Nov 2005, In: Pharmacoepidemiology and Drug Safety. 14, 11, p. 769-773

    Research output: Contribution to journal › Article › peer-review

20. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 11 Nov 2005, In: Value in Health. 8, 6, p. A192

    Research output: Contribution to journal › Article › peer-review

21. 2006
22. Published

    Beyond registration: measuring the public health potential of new treatments for Malaria in Africa.

    Hughes, D., Lang, T., Hughes, D. A., Kanyok, T., Kengeya-Kayondo, J., Marsh, V., Haaland, A., Pirmohamed, M. & Winstanley, P., 1 Jan 2006, In: Lancet Infectious Diseases. 6, 1, p. 46-52

    Research output: Contribution to journal › Article › peer-review

23. Published

    Health economic aspects of patient non-compliance

    Hughes, D., Hughes, D. A., Davies, M. (Editor) & Kermani, F. (Editor), 1 Jan 2006, Patient Compliance: Sweetening the Pill. 2006 ed. Gower Publishing, p. 23-40

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

24. Published

    Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Jan 2006, 2006 ed. Unknown.

    Research output: Book/Report › Commissioned report

25. Published

    Improving Outcomes for People with Sarcoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 1 Jan 2006, 2006 ed. Unknown.

    Research output: Book/Report › Commissioned report

26. Published

    Less is more: Medicines that require less frequent administration improve adherence, but are they better?

    Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 3, p. 211-213

    Research output: Contribution to journal › Article › peer-review

27. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Jan 2006.

    Research output: Contribution to conference › Paper

28. Published

    Rationing of drugs for rare diseases.

    Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 4, p. 315-316

    Research output: Contribution to journal › Article › peer-review

29. Published

    Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Feb 2006, Unknown.

    Research output: Book/Report › Commissioned report

30. Published

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Mar 2006.

    Research output: Contribution to conference › Paper

31. Published

    Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.

    Simpson, J. A., Hughes, D., Manyando, C., Bojang, K., Aarons, L., Winstanley, P., Edwards, G., Watkins, W. A. & Ward, S., 1 Mar 2006, In: British Journal of Clinical Pharmacology. 61, 3, p. 289-300

    Research output: Contribution to journal › Article › peer-review

32. Published

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

33. Published

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

34. Published

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

35. Published

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 May 2006.

    Research output: Contribution to conference › Paper

36. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments

    Hughes, D. & Hughes, D. A., 1 May 2006.

    Research output: Contribution to conference › Paper

37. Published

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 May 2006, In: Quarterly Journal of Medicine. 99, 5, p. 350-351

    Research output: Contribution to journal › Article › peer-review

38. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Jun 2006.

    Research output: Contribution to conference › Paper

39. Published

    Prescription fee exemption research study

    Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Jun 2006.

    Research output: Contribution to conference › Paper

40. Published

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Sept 2006.

    Research output: Contribution to conference › Paper

41. Published

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Nov 2006.

    Research output: Contribution to conference › Paper

42. 2007
43. Published

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

44. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109

    Research output: Contribution to journal › Article › peer-review

45. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

46. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

47. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

48. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

49. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

50. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

51. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

52. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

53. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

54. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report